Concepedia

Tamta Makharadze

TM

Statistics

Publications

12

Citations

2K

H-Index

11

Active since

2021

Affiliations

Regeneron (United States)(Current)

Chelyabinsk Regional Clinical Oncology Center

David Tvildiani Medical University

Polish Mother’s Memorial Hospital Research Institute

Tbilisi State Medical University

Tamta Makharadze is an author at Regeneron (United States) specializing in oncology, medicine, and lung cancer pharmacotherapy.

ORCID

Publications per year

2021–2024

12

Publications

12

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 799 citations

, , +13

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 522 citations · Full text

, , +17

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 301 citations · Full text

, , +15

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze et al. · Journal of Thoracic Oncology · 2023 · 98 citations · Full text

, , +15

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 82 citations · Full text

, , +13

1–5 of 12